FGF-21 as a Potential Biomarker for Mitochondrial Diseases

Author(s): Leila Motlagh Scholle*, Diana Lehmann, Marcus Deschauer, Torsten Kraya, Stephan Zierz

Journal Name: Current Medicinal Chemistry

Volume 25 , Issue 18 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer


The diagnosis of mitochondrial diseases is still challenging due to clinical and genetical heterogeneity. The development of advanced technologies including Whole-Exome- Sequencing (WES) and Whole-Genome-Sequencing (WGS) has led to improvements in genetic diagnosis. However, a reliable biomarker in serum could enhance and ease the diagnosis and indeed reduce the need for muscle biopsy. Several studies suggest Fibroblast growth factor 21 (FGF-21) as a biomarker for diagnosis in mitochondrial disorders. It is known, that in patients with mitochondrial disorders, the expression of FGF-21 gets elevated in an effort to counteract the underlying metabolic deficiency. The growth and differentiation factor 15 (GDF-15) has been described as a potential biomarker for mitochondrial diseases, too. In the present review, a literature research, using PubMed database about the reliability of FGF-21 as a biomarker for mitochondrial disorders and its comparison with GDF-15 has been performed.

Keywords: FGF-21, Mitochondrial diseases, biomarker, GDF-15, COX, diagnosis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [2070 - 2081]
Pages: 12
DOI: 10.2174/0929867325666180111094336
Price: $65

Article Metrics

PDF: 66
HTML: 21
PRC: 2